Bad Blood
Secrets and lies in a Silicon Valley Startup
by John Carreyrou
The 60-Second Take
In Bad Blood, journalist John Carreyrou reconstructs the rise and fall of Theranos, the blood-testing startup that promised a medical revolution and delivered systematic fraud. The book is the definitive account of how a fake business reached a $9 billion valuation and the governance, investor, and regulatory failures that let it happen. Required reading for board members, investors, and anyone responsible for diligence.
Bad Blood: The Anatomy of a Silicon Valley Fraud
In its peak year, Theranos was valued at $9 billion. Its founder, Elizabeth Holmes, was the youngest self-made female billionaire in the world. The company claimed to have invented a revolutionary blood-testing device that could run hundreds of tests from a single drop of blood. The board included two former U.S. secretaries of state, a former U.S. secretary of defense, and a four-star general. The story was a Silicon Valley fairy tale.
It was also almost entirely a lie.
John Carreyrou, the Wall Street Journal reporter whose investigative work broke the Theranos story open, wrote Bad Blood: Secrets and Lies in a Silicon Valley Startup as the definitive account of what actually happened inside the company. The book reads like a thriller. It also serves as one of the sharpest case studies in modern corporate fraud, governance failure, and the cultural conditions that let a fake business reach near-public-company status.
What You'll Learn
The specific lies Theranos told and how they passed initial scrutiny
The governance breakdowns that let the fraud scale
The cultural patterns that distinguish a "fake it til you make it" startup from a fraudulent one
The warning signs that should have surfaced years earlier
Practical lessons for board members, investors, and operators
The Fraud Itself
Theranos claimed its Edison device could run a comprehensive panel of blood tests from a few drops drawn from a finger prick. In reality, the device almost never worked. Test results were unreliable. Many of the tests Theranos sold were actually run on commercial machines purchased from competitors, hidden behind a curtain in the lab.
Carreyrou documents the specific deceptions in detail. Modified third-party machines passed off as Theranos technology. Investor demos rigged to produce predetermined outputs. Patient blood samples diluted to fit machine specifications, producing systematically inaccurate results. Internal employees who raised concerns were threatened with litigation, fired, or driven out.
What makes the story unusual is not that fraud occurred. It is that the fraud persisted for more than a decade despite the involvement of high-profile investors, a celebrated board, and partnerships with Walgreens and Safeway. The system did not work.
How Governance Failed at Every Layer
The Theranos board was assembled for credibility rather than competence. Henry Kissinger, George Shultz, James Mattis, and others lent their names but had no scientific or medical expertise. They did not ask the right questions. When concerns reached them, the founder's charisma deflected them.
The investors followed a similar pattern. The lead investors were wealthy individuals and family offices, not venture capital firms with deep healthcare expertise. The major medical and pharmaceutical companies who could have evaluated the technology had passed early on. The capital came from people who did not know enough to spot the lies and trusted the people they assumed did.
The audit and regulatory function failed too. The company avoided FDA oversight for years by claiming its tests were lab-developed rather than commercial products. Inspectors who visited the facility were shown only the parts of the operation that worked. The complaint process for whistleblowers was paralyzed by aggressive legal threats.
The lesson is structural. A board, an investor base, an audit function, and a regulatory regime all assumed the others were doing the work. None of them was.
Fake It Til You Make It Versus Fraud
Carreyrou is careful to distinguish Theranos from the routine optimism of early-stage startups. Many founders promise more than the product currently delivers. The hope is that the product will catch up to the pitch by the time it matters. That is not fraud. It is the standard rhythm of startup commerce.
Theranos crossed several specific lines.
It told customers that tests had been performed when they had not, or had been performed on equipment the company did not own.
It produced demo results that were manipulated, not generated by the actual device.
It signed major commercial agreements based on misrepresentations about what the technology could do.
It published clinical claims and accuracy figures that were known internally to be false.
It used aggressive legal tactics to suppress employees who raised concerns and journalists who began investigating.
Each line is a clear ethical and legal boundary. Crossing them is not a gray area.
Warning Signs Worth Memorizing
For board members, investors, and operators, the book provides a useful list of patterns that should trigger deeper investigation.
Excessive secrecy about how the product actually works. A trade secret protects implementation. A wall around basic mechanism of action protects deception.
Aggressive litigation against employees and journalists. Companies with strong products rarely need to sue their critics.
Boards composed for prestige rather than function. When the directors cannot meaningfully evaluate the product, they cannot oversee it.
Demos that the company tightly controls. Real products work when the audience picks the test.
A culture of fear inside the company. Whistleblowers existed at Theranos. They were silenced for years.
Founder narratives that resist any scrutiny. A founder who treats every hard question as a personal attack is hiding something.
None of these alone is proof of fraud. The cluster is a strong signal that something is wrong.
A Quick Start Guide for Spotting Fraud Risk
Adapt these checks for your own due diligence, hiring, or governance work.
Demand independent verification. Whatever the company claims, who has independently verified it? If the answer is "no one," dig further.
Read the lawsuits and settlements. Pattern matters. Multiple suppressed whistleblowers is a pattern.
Test the chain of evidence. Where did the test result actually come from? On whose machine? Verified by whom?
Pressure test the board. Does the board contain anyone with the domain expertise to evaluate the product technically? If not, why not?
Map the regulatory posture. Are they avoiding oversight by choice? What is the rationale?
Final Reflections
Bad Blood is gripping reading on its own terms, but its lasting value is as a structural case study. The Theranos collapse was not a single point of failure. It was the simultaneous failure of governance, investor diligence, regulatory oversight, employment law, and journalistic access. Each layer assumed another was holding the line. The result was a near-public-company-scale fraud built on a product that almost never worked. For anyone serving on a board, evaluating an investment, or running due diligence, the patterns Carreyrou documents are worth memorizing.
Business Floss is reader-supported. When you use our links we may earn an affiliate commission that helps us keep the site running. Thank you for your support!
